0808 GMT - Novo Nordisk's downgraded guidance assumes a meaningful uplift of Wegovy volumes in the second half of the year and analysts at Morgan Stanley think the top end of the new guidance is still demanding. The guidance cut implies a 1% cut to consensus sales and EBIT at constant exchange rates but a 4% cut on sales and 6% cut on EBIT including currencies, the bank says. First quarter Wegovy sales missed expectations by 7%, impacted by destocking in the U.S. and compounding competition. Novo Novo also noted lower realized prices. Ozempic beat by 3%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
May 07, 2025 04:08 ET (08:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.